Vaccination against polio should not be stopped

Nature Reviews Microbiology

Volumn 5, Issue 12, 2007, Pages 952-958

  Chumakov, Konstantin ^a   Ehrenfeld, Ellie ^b   Wimmer, Eckard ^c   Agol, Vadim I ^d  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; ENDEMIC DISEASE; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROMOTION; HUMAN; IMMUNIZATION; INCIDENCE; INFECTION CONTROL; PHENOTYPIC VARIATION; POLIOMYELITIS; POLITICS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; STRAIN DIFFERENCE; VACCINATION; VIRUS IMMUNITY; VIRUS VIRULENCE; WILD TYPE;

DISEASE OUTBREAKS; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; VACCINATION;

POLIOVIRUS;

EID: 36248962716     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1769     Document Type: Article

References (61)

1. Arita, I., Nakane, M. & Fenner, F. Public health. Is polio eradication realistic? Science 312, 852-854 (2006).
2. Minor, P. D. Polio eradication, cessation of vaccination and re-emergence of disease. Nature Rev. Microbiol. 2, 473-482 (2004).
3. Apparent global interruption of wild poliovirus type 2 transmission. MMWR 50, 222-224 (2001).
4. Sabin, A. & Boulger, L. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1, 115-118 (1973).
5. Agol, V. I. Molecular mechanisms of poliovirus variation and evolution. Curr Top. Microbiol. Immunol. 299, 211-259 (2006).
6. Agol, V. I. Vaccine-derived polioviruses. Biologicals 34, 103-108 (2006).
7. Minor, P. & Almond, J. in Molecular Biology of Picornaviruses (eds Semler, B. & Wimmer, E.) 381-390 (American Society of Microbiology, Washington DC. 2002).
8. Kew, O. M., Sutter, R. W., de Gourville, E. M., Dawdle, W. R. & Pallansch, M. A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59, 587-635 (2005).
9. Mueller, S., Wimmer, E. & Cello, J. Poliovirus and poliomyelitis: A tale of guts, brains, and an accidental event. Virus Res. 111, 175-193 (2005).
10. Nkowane, B. M. et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 257, 1335-1340 (1987).
11. Prevots, D. R., Sutter, R. W., Strebel, P. M., Weibel, R. E. & Cochi, S. L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch. Pediatr. Adolesc. Med. 148 479-485 (1994).
12. Kew, O. et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296 356-359 (2002).
13. Lipskaya, G. et al. Geographical genotypes (geotypes) of poliovirus case isolates from the former Soviet Union: Relatedness to other known poliovirus genotypes. J. Gen. Virol. 76, 1687-1699 (1995).
14. Update on vaccine-derived polioviruses. MMWR 55, 1093-1097 (2006).
15. Melnick, J. in Virology (ed. Fields, B) 739-794 (Raven, New York, 1985).
16. MacLennan, C. et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immuno-deficient man. Lancet 363, 1509-1513 (2004).
17. Halsey, N. A. et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. World Health Organ. 82 3-8 (2004).
18. Gavrilin, G. V., Cherkasova, E. A., Lipskaya, G. Y., Kew, O. M. & Agol, V. I. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: A unifying model. J. Virol. 74, 7381-7390 (2000).
19. Martin, J., Dunn, G., Hull, R. Patel, V. & Minor, P. D. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74, 3001-3010 (2000).
20. Yang, C. F. et al. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79, 12623-12634 (2005).
21. Hovi, T, Lindholm, N. Savolainen, C., Stenvik, M. & Burns, C. Evolution of wild-type 1 poliovirus in two healthy siblings excreting the virus over a period of 6 months, J. Gen. Virol. 85, 369-377 (2004).
22. Martin, J. et al. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78, 13839-13847 (2004).
23. Poliovirus infections in four unvaccinated children - Minnesota, August-October 2005. MMWR 54, 1053-1055 (2005).
24. Combiescu, M. et al. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania. Arch. Virol. 152, 727-738 (2007).
25. Cherkasova, E. et al. Microarray analysis of evolution of RNA viruses: Evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc. Natl Acad. Sci. USA 100, 9398-9403 (2003).
26. Cherkasova, E. A. et al. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76, 6791-6799 (2002).
27. Blomqvist, S. et al. Characterization of a highly evolved vaccine-derived pollovirus type 3 isolated from sewage in Estonia. J. Virol. 78, 4876-4883 (2004).
28. Cernakova, B. et al. Isolation of vaccine-derived polioviruses in the Slovak Republic. Eur. J. Clin. Microbiol. Infect. Dis. 24 438-439 (2005).
29. Horie, H. et al. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan. J. Med. Virol. 68, 445-451 (2002).
30. Shulman, L. M. et al. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38, 3729-3734 (2000).
31. Dowdle, W. et al. Containment of polioviruses after eradication and OPV cessation: Characterizing risks to improve management. Risk Anal. 26, 1449-1469 (2006).
32. Cello, J., Paul. A. V. & Wimmer, E. Chemical synthesis of poliovirus cDNA: Generation of infectious virus in the absence of natural template. Science 297, 1016-1018 (2002).
33. Tian, J. et al. Accurate multiplex gene synthesis from programmable DNA microchips. Nature 432, 1050-1054 (2004).
34. Tumpey, T M. et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310, 77-80 (2005).
35. Wimmer, E. The test-tube synthesis of a chemical called poliovirus. The simple synthesis of a virus has far-reaching societal implications. EMBO Rep. 7, S3-9 (2006).
36. MacKenzie, D. Eradicating polio leaves people defenceless. New Sci. 2562, 8 (2006).
37. Aylward, R. B., Sutter, R. W. & Heymann, D. L. Policy. OPV cessation - the final step to a "polio-free" world. Science 310, 625-626 (2005).
38. Heymann, D. L., Sutter. R. W. & Aylward, R. B. A vision of a world without polio: The OPV cessation strategy. Biologicals 34, 75-79 (2006).
39. Karotkova, E. A. et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: A possible scenario for the future. J. Virol. 77, 12460-12465 (2003).
40. John, T. J. Two good reasons to drop type 2 virus from oral polio vaccine. Lancet 364, 1666 (2004).
41. Peart, A. F., Rhodes, A. J. et al. An outbreak of poliomyelitis in Canadian Eskimos in wintertime. Can. J. Public Health 40, 405-419 (1949).
42. Rhodes. A. J. & Chapman, M. Some observations on interference between neurotropic viruses. Can. J. Res. 27, 341-348 (1949).
43. Rutty, C. The Middle Class Plague: Canada and the Pblio Years. Thesis, Univ. Torronto (2005).
44. Burnet, F Viral and infectious diseases. Annu. Rev. Med. 2, 1-24 (1951).
45. Tebbens, R. J. et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 26; 1471-1505 (2006).
46. Thompson, K. M., Duintjer Tebbens, R. J. & Plallansch, M. A. Evaluation of response scenarios to potential polio outbreaks using mathematical models, Risk Anal. 26, 1541-1556 (2006).
47. Thompson, K. M. et al. Development and consideration of global policies for managing the future risks of poliovirus outbreaks: Insights and lessons learned through modeling. Risk Anal. 26, 1571-1580 (2006).
48. Thompson, K M. & Tebbens, R. J. Eradication versus control for poliomyelitis: An economic analysis. Lancet 369, 1363-1371 (2007).
49. Agol, V. I., Pilipenko, E. V. & Slobodskaya, O. R. Modification of translational control elements as a new approach to design of attenuated picornavirus strains. J. Biotechnol. 44, 119-128 (1996).
50. Kohara, M., Abe. S., Yoshioka, I. & Nomoto. A. Development of candidates for new type 2 and type 3 oral poliovirus vaccines. Dev. Biol. Stand. 78, 141-148 (1993).
51. Macadam, A. J. et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: Relevance to poliomyelitis eradication. J. Virol. 80, 8653-8663 (2006).
52. Toyoda, H., Yin, J., Mueller, S., Wimmer. E. & Cello, J. Oncolytic treatment and cure of neurablastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 67, 2857-2864 (2007).
53. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N. Engl. J Med. 356, 1536-1544 (2007).
54. Melnick, J. L. Combined use of live and killed vaccines to control poliomyelitis in tropical areas, Dev. Biol. Stand. 47, 265-273 (1981).
55. Oduntan, S. O. & Familusi, J. B. An appraisal of polio immunization in Nigeria and other tropical African Countries. Niger. Med. J 9 645-649 (1979).
56. Salk, D. & Salk, J. Vaccinology of poliomyelitis. Vaccine 2, 59-74 (1984).
57. Workshop Report, Committee on Development of a Polio Antiviral and Its Potential Role in Global Poliomyelitis Eradication (ed. Press, T. N. A.) (National Research Council of the National Academies, Washington DC, 2006).
58. Yakovenko, M. L. et al. Antigenic evolution of vaccine-derived polioviruses: Changes in individual epitopes and relative stability of the overall immunological properties. J. Virol. 80, 2641-2653 (2006).
59. Arita, M. et al. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J. Virol. 79 12650-12657 (2005).
60. Jiang, P. et al. Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses: Implications for global poliovirus eradication. Proc. Natl Acad. Sci. USA 104, 9457-9462 (2007).
61. Update an vaccine-derived polioviruses - worldwide, January 2006-August 2007. MMWR 56, 996-1001 (2007).